

## **ELIMINATION OF SHELF LIFE OF ALL BLOOD COMPONENTS**

**Our proven technology was originally discovered and proven in the sixties under a Naval contract with Linde Corporation a division of Union Carbide.**

**Once proven and ready for introduction into the market. Funding was cut and the technology lied dormant until 2011 when we picked up the technology and submitted the patents (which expired) and have now discovered that this technology has broadened beyond to Red cells (as originally contracted) but to now include Platelets, white cells and Plasma. As well as eliminating most if not all contaminants in blood.**

**We will be also be introducing a new protectant that will not have to be removed prior to use.**

**Our technology will not only save more lives, but save hospitals and blood centers millions of dollars.**

## **BLOOD SUPPLY**

### **When tragedy strikes**

**Natural disasters, Hurricanes Harvey/Maria**

**Earthquakes Mexico**

**Tragedies Las Vegas**

**History has proven our inability to organize and deliver the necessary resources and continues to be a challenge.**

**Timing and preparedness is essential.**

**Blood is a critical resource to save lives.**

**C-levelclone/Cryomedic Technologies has the answer to ensure all the blood supply that is needed is available and ready go.**

**We have eliminated shelf life of all Blood components(see attached documents).**

## SAVING MORE LIVES

Good Day

Hope all is well.

In brief, I would like to explain our technology to you.

We have proven patented technology that has eliminated shelf life of **ALL BLOOD COMPONENTS (Red Cells, Platelets, White Cells, and Plasma).**

We will also be introducing a **New Protectant** that will eliminate the need to be removed prior to transfusion. Thereby eliminating the need to be washed prior to transfusion.

In early research, we will eliminate most if not all contaminants in blood.

I have included three documents for your review.

- 1) **Market size for just Platelets alone.**
- 2) **The list of companies we will have a significant impact on.**
- 3) **LOI from Gold Back Bonds, LLC to help fund Drone delivery options, as well as new portable device using our patented heat transfer rate to room temperature as a non-water solution.**

I look forward to speaking with you and discussing our **Game Changing Technology.**

Best wishes

Jimmy Walker

Founder/Chairman

C-Levelclone

[jwalker@c-levelclone.com](mailto:jwalker@c-levelclone.com)

617-799-4211

**ELIMINATION OF SHELF LIFE OF ALL BLOOD COMPONENTS**

Financial Projections

**Model A**

**Platelets**

Number of units disposed of US (2011)	650,000 (1)	
FMV of each unit(mid-price)	\$ 625	
Value of disposed units (2011)	\$ 406,250,000	
Global Market annual revenue CLC process	\$ 4,062,500,000	
Brought forward to 2015(growth @2.5%PA)	\$4,484,239,868	
Assume CLC @25% of market	\$1,121,059.967	
Royalty rate @ 10%		\$112,105,997

**Model B Whole Blood**

**Becker's Hospital Review**

**Hospital rankings by size**

Number 1 with 2272 beds	\$74,248,366
Number 100 with 674 beds	\$22,026,144
Number 27 John Hopkins	\$30,000,000
With 918 beds	

Mean Budget (number 1 and 100)	\$48,137,255
US Blood Management Budget top 100 hospital US	\$4,813,725,490

<b>Discount by 2/3 = remainder 1/3</b>	<b>\$ 1,602,970,588</b>
<b>CLC process savings @ 15%</b>	<b>\$ 240,445,588</b>
<b>Globalize (times 4) annual revenue CLC Process</b>	<b>\$ 961,782,352.940</b>
<b>Process Royalty @ 7.5%</b>	<b>\$ 72,133,676</b>
<b>Total Royalties annual</b>	<b>\$ 184,239,673</b>

**1) the 2011 National Blood Collection and Utilization Survey Report**

Our technology will have a significant impact on some major companies currently in the Blood Market.

**Haemonetics-** currently a \$1.0B company. Spent \$50M for a solvent that would extend the shelf life of Red Cells by 14, or 56 days' vs 42. They also supply the units isolates platelets from whole blood. A 2-hour process for donor and a very expensive machine to process. Our technology you just draw blood as you normally would.

**Immunetics-** BacTx test allows hospitals to readily facilitate efficient testing of Platelets with a rapid testing system for bacterial detection that meets the proposed FDA guidance. The result is a safer platelet supply, providing transfusion services with a "last look" at the platelet unit just prior to transfusion

**CERUS-** Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus, and bacteria, as well as emerging pathogens such as Chikungunya, malaria, and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of the Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development.

**Verax Biomedical-** Producer of the Platelet PGD Test. The only test for bacterial contamination in Platelets, as a safety measure by the FDA. The test can now also be used to extend the dating of apheresis platelets in plasma, the most common Platelet type transfused in the U.S. from 5-7 days.

**New Health Sciences-** The ability to store RBCs and other components for extended periods of time have dramatically expanded the availability and use of transfusion as a life-saving therapy. However, as soon as whole blood is collected from a donor, red blood cells begin to degrade. RBCs experience progressive biochemical and biomechanical changes during storage, collectively called the "storage lesion", that result in compromised physiological functions. The US FDA stipulates that red blood cells may be stored for no more than 42 days with proper refrigeration and additive solutions. In other countries, storage is limited to just 35 days. By storing blood under oxygen-depleted conditions, the Hemanext Storage System aims to reduce this degradation and improve the function of an RBC by removing a primary root cause of this degradation — oxidative damage.

**Dr. Jonathan Thon Ph.D Research and Associate Professor Brigham and Women's Hospital.**

What he is doing is reproducing physiology by tapping a potentially unlimited source of the parent cells derived from the stem cells against the porous membrane, and expose them to physiological shear stresses characteristic of flowing blood trigger new platelet production.

These companies with their technology add significant cost to an already expensive process.

Blood Management within a hospital is one of the most expensive, and very difficult budgets to manage.

.We have spent the last 5 years researching and proving that our process will do the following:

- 1) Eliminate the shelf life of Platelets, Red Cells, Plasma, and, White Cells
- 2) Eliminate most if not all contaminants in blood
- 3) We have a new FDA approved (for other consumable products) cryo-Protectant. Which will eliminate the need to wash out prior to use?  
The ratio of cryo- protectant vs blood is 99% blood 1% cryo-protectant.  
The current ratio is 60% blood 40% cryo-protectant (which either Glycerol or DMSO is the protectant of choice).
- 4) No need to have separate donation process for Platelets, Plasma, or White Cells. You just draw blood as you normally would, use our process and all the components of blood would be available.
- 5) No capital investment is required, as all hospitals and blood centers have Freezers.

The financial savings to both hospitals and blood centers is significant and will instantly save them millions of dollars and billions over the years.

# GOLD BACKED BONDS LLC

212 7<sup>th</sup> Ave., Helena, Montana 59601

Jimmy Walker, CEO and Director

C-Levelclone

68 Marathon Street, Arlington MA 02474

June 8, 2017

Dear Jimmy:

## LETTER OF INTENT

Further to our many discussions and email communications, I have now completed my due diligence on your company, and discussed my findings with the directors of Gold Backed Bonds. I am pleased to inform you that this letter is our commitment to you: Gold Backed Bonds LLC or a wholly owned subsidiary thereof intends to move forward to fund your company. Our plan is to create a bond of between \$100 Million USD and \$500 Million dollars in order to enable you to commercialize your technology domestically and internationally. The exact amount of the funding is to be determined based upon your requirements and further discussions regarding your business plan.


The exact timing of our commitment has yet to be precisely determined and is contingent upon our closing of the bond that we are currently creating for an specialty oil refinery in Cheyenne Wyoming. It is hoped and anticipated that this bond will close soon, perhaps as soon as this month.

As you are aware, the bond that we intend to create can cost in the range of \$600,000-\$700,000 USD. Moreover, we will be collaborating with Delmorgan Co. on this project and their fee is \$150,000. Although it is against our usual company policy to do so, in this instance it is our intention to provide you with a bridge loan to cover these costs. We propose that the bridge loan will be repayable from the proceeds on the bond. The terms of the loan will be detailed at a later date but our intention is to make it on terms that we think will be acceptable and attractive to you.

As soon as we have closed the bond that we are currently finalizing, we will be in touch with you again so

act.

Best wishes,



we can move forward together on this exciting project.

Dr. Ted Robinson, Senior Advisor

Gold Backed Bonds LLC